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Summary.-A hypothesis is proposed that tumour lysis may be an important factor
affecting blood levels of CEA. This has been explored in an experimental study with a
model tumour system, consisting of immune-deprived mice bearing human CEA-
producing tumours. Using agents such as irradiation, chemotherapeutic drugs,
diphtheria toxin and techniques such as cryosurgery, it has been shown that tumour
lysis is important when it is both rapid and extensive. The extent to which this may
occur in patients remains uncertain, except in rare instances of dramatic response
of malignant disease to treatment.
WHEN blood CEA levels are used for
monitoring response of malignant disease
to chemotherapeutic agents, the correla-
tion is often imprecise. Although over a
long term, serial estimations will reflect
disease progress (e.g. Steward et al., 1974;
Borthwick et al., 1977; Mayer et al., 1978;
Waalkes et al., 1980) paradoxical or dis-
cordant changes in CEA occur in up to
3000 ofpatients during the early and inter-
mediate periods (Ravry & Moertel, 1974;
Shani et al., 1978). Furthermore, wide
diurnal variations (up to 3-fold) may
occur during chemotherapy (Skarin et al.,
1974; Young et al., 1976) and even cases
with low pretreatment blood CEA levels
have been reported to develop grossly
elevated levels in the early phase of
remission (Waalkes et al., 1980). A similar
response often occurs after radiotherapy
when, in addition, levels commonly re-
main elevated for periods of up to 6 weeks
before gradually falling (Khoo & Mackay,
1976; Donaldson et al., 1976; Sugarbaker
et al., 1978). Of particular interest is that
these elevations are most common during
the mid-course of treatment, which is
uisually the time when tumour breakdown
is greatest. Whilst there may be many
other factors involved, the possibility
should therefore be considered that these
changes may be due to tumour necrosis.
In an investigation to determine whether
this may be the case, an animal model
system consisting of immune-deprived
mice bearing human CEA-producing tum-
ours has been used.
MATERIALS AND METHODS
Human tumours already established in
transplant passage to immune-deprived mice.
which had been found on screening to produce
high titres of CEA in the blood of host mice,
were used. These consisted of 4 colorectal
(HK1, 6, 7, 9), one breast (S32) and one lung
(p246) tumours. Their characteristics, and the
techniques of immune-deprivation, grafting
and tumour measurement, together with
methods for measuring circulation CEA levels
have previously been described in the pre-
ceding article (Quayle, 1982). Mice bearing
bilateral s.c. implants ofthese tumours which
had each grown to 1 cm3 were usedthrough-
out.
Two main approaches were used. In the
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first, tumour lysis was induced by direct
techniques in situ, which in effect produced
tissue ischaemia; whilst in the second, in-
direct procedures involving drugs, toxins and
irradiation were used.
Various direct methods were initially tried,
such as simple surgical excision and reimplan-
tation, injections of tumour lysates, rich in
CEA and cryosurgery. With the exception of
the latter, these were technically unsuccessful,
probably because the means of immediate
entry of CEA into the circulation had effect-
ively also been destroyed or were inadequate.
Cryo-technique
This used a standard liquid-N2 cryo-
surgical apparatus with a special fine needle
probe adaptation. Whenthe probewaspushed
into the centre of a tumour, central liquified
necrosis would occur around the track, with
sparing of the periphery of the tumour and
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its vascular connections. The procedure was
performed under general ether anaesthesia
through a small incision. A similar sized
needle, not attached to the cryo-apparatus,
was used for a control tumour-bearing group.
Blood was collected at 12, 24 h and then
daily intervals for a total of 4 days. The mice
were then killed and post-mortem analysis
of the tumour performed.
The results are illustrated in Fig. 1. In
10/15 cryo groups there was an abrupt fall in
CEA, but in the 5 in which this failed to
occur there was a sharp elevation, usually
>3 x the pretreatment titre, during the
first 24 h. No significant change occurred in
the control group. The reason for the abrupt
fall in CEA in most of the cases is probably
because cryosurgery had removed the blood
supply within the tumour arising from its
over-energetic use. Indeed there was definite
macroscopic evidence ofexcessive coagulative
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FIG. 1. Cryosurgical necrosis vs blood CEA.
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necrosis in 4 cases, though there was no
difference in the others.
Indirect procedures
Cytotoxic drugs. Previous screening of
p246 lung (Mitchley et al., 1977) and HK6
colon (Nowak et al., 1978) had revealed
response to the cytotoxic agent hexamethyl-
melamine (HMM). S32 breast response had
not previously been assessed, but cyclo-
phosphamide (CTX) was selected because of
its reputation as one of the most effective
agents in the treatment of breast-cancer
patients (Carter, 1976). The toxicology of
these drugs in mice had previously been
defined in the Pharmaceutical and Toxi-
cology Department at the Chester Beatty
Institute. Schedules were selected to give
maximal therapeutic effect, as shown below:
Drug
Hexamethyl-
melamine
(HMM)
Cyclophos-
phamide
(CTX)
LD50
113 mg/kg/i.p.
daily for
7 days
350 mg/kg/
i.p.
Treatment
schedule
100 mg/kg/i.p.
daily for
5 days
200 mg/kg/
i.p.
Individual dosage was calculated for the
average weight of mice in each group. Since
all mice in each batch were of the same age
there was little disparity. Administration was
by i.p. infusions in 200,l aqueous solution
in the case of CTX and arachis oil for HMM.
Control mice received solvent only.
Irradiation. Mice bearing bilateral im-
plants of S32 breast and p246 lung tumours
were used. They were individually anaesthe-
tized by i.p. infusions of pentobarbitone
combined with penthrane inhalation, and
then encased in a lead cylinder which had a
small lateral aperture. Each implant in turn
was positioned without tension on the outer
aspect of the cylinder through the aperture.
held by a small clip lightly applied to overly-
ing skin and then exposed to 100 Gy irradia-
tion delivered by an overhead 250 kV X-ray
machine. Control mice were anaesthetized
only.
Diphtheria toxin.-This agent was used
because of its strong cytotoxic effect on
human tumours maintained in immune-
deficient mice, and its mild side effects in the
hosts compared to humans (Kaplan et al.,
unpub.). The toxin was provided by Dr P.
Thorpe at the Immuno-biology Department
of the Chester Beatty Research Institute.
Toxicity studies revealed an LD50 400 jg/kg
in B mice. After a successful pilot study 40 ,ug/
kg in 200 jig i.p. was used throughout.
Control mice were given the same quantity
ofsaline only.
RESULTS
Responses of tumours.-For the purpose
of analysis, treatment responses have been
expressed as a percentage change in tum-
our volume over the study period and are
summarized in Table I. It will be seen
that in almost all cases untreated controls
continued to grow. Dramatic responses
followed diphtheria toxin, particularly in
the colonic tumour groups, in which there
was usually a size reduction >50%0 by
the 2nd week after treatment. S32 breast
tumours also responded but to a lesser
extent. The lung tumour p246, however,
showed no evidence of regression.
In the HK9 colon group the response
was complete and the residual tiny nodules
were found on histology to consist of
TABLE I. Tumour treatment responses
Change in tumour volume percentage (average per mouse)
Before treatment/10-15 days after treatment
Controls
Diphtheria toxin
(40 ,4g/kg)
X-rays (100 Gy)
CTX (200 mg/kg)
HMM I1 00 mg/kg for 5 days)
* Tn parentheses, nuimber of mice.
Colon
A~~~~~~~~~~~~~
HK1 HK6 HK7 HK9
162 (5)* 150 (7) :323 (3) 140 (8)
50 (6) 45 (12) 45 (4) 19 (16)
Lung
P246
150 (9)
145 (10)
Breast
832
129 (9)
60 (6)
84 (6) 85 (6)
98 (8)
51 (5) 122 (6)
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necrotic debris and granulation tissue
only. In other groups there was often
evidence of groups of normal-looking cells
xvithin large areas of amorphous necrotic
(lebris, and regrowth subsequently often
occurred.
Less dramatic tumour responses occur-
red following irradiation, though on aver-
age, size reduction of 15%0 was usuallv
obtained within 2 weeks.
The effects of HMM and CTX were
varied and generally smaller. There was
uisually a size reduction of 50%0 in the
p246 group but in the 832 and HK6
groups the responses were small and less
frequent. In no case was complete remis-
sion obtained by these drugs.
Effects of CEA levels
Controls. A random (laily variation
was seen in individual mice in each tum-
our group; example Fig. 2. Although this
was usually small, in some mice this could
sometimes be as high as 60%. The range
of variation appeared to be independent
of individual CEA blood levels, individual
tumour size, and the frequency of vene-
section.
Treatment groups. The overall response
of CEA levels following treatment is
summarized in Table II. Examples of
individual groups are illustrated in Figs
3-5. It will be readily apparent that the
most dramatic responses occurred follow-
ing diphtheria toxin which reflects the
overall tumotur response. In many cases
peak elevation of plasma CEA levels more
than 10-fold occurred, often exceeding the
range of sensitivity of the assay. There
were few examples of peak elevation,
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FIG. 2.-CEA bloo(d levels in controls: intra-
assay error is shown in some cases.
however, in response to cytotoxic drugs,
in which the most noticeable effect was a
considerable increase in daily variation
(often by as much as I100%) and this
appeared to be independent of tumour
response.
There were several examples in which
paradoxical responses of CEA in relation
to tumour response occurred. In particu-
lar, the most responsive tumour group to
diphtheria toxin was the HK9 colon group,
which was associated with the least uni-
form or extensive in terms of peak CEA
elevations, but CEA eventually completely
disappeared from the blood. This was
demonstrated to a lesser degree following
radiation to the S32 group, and following
cytotoxic drugs in HKG as well as S32
groups.
There were temporal differences accord-
TABLE II.-Incidence ofpeak elevations of (CEA
Percentage Inice vith increase(l CEA levels
Diplhthleria toxil
X-ray
CTX
HMM
Extent of
increase
(multiplc)
> :3 x
>2x
> 2 x
> 2 x
Coloin
HKI HK6 F
66 (6)* 75 (12) 25
20 (6)
LuIng
HK7 HK9 P246
5 (4) 19 (16) ( (10)
50 (6)
60 (5)
In )aIeIitheses, number' mice.
Breast
832
85 (7)
66 (6)
25 (8)
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FiG. 3. CEA bloo)0 levels following (liplitlieria toxin (in parentheses, percentage change
in ttumourl volume).
ing to the treatment used. Following
diphtheria toxin, rises in CEA became
apparent usually in the first 12-24 h, and
seldom within the first 6 h, or after 48 h.
In most cases CEA would then remain at
these high peaks for 24-48 h, but occasion-
ally would persist for up to 5 days. The
subsequent fall in CEA was rapid, usually
returning to pretreatment levels in 24 h
and thereafter gradually to zero over a
further 2-4 days in almost all cases. In
contrast, after radiotherapy, there was
often a 48 h delay before rises in CEA
became apparent, and the subsequent fall
in CEA below pretreatment titres tended
to be more prolonged, with CEA usually
detectable in the blood even at 17 days.
In the tumour group responding to cyto-
toxic drugs (p246) there was a gradual
trend ofCEA downwards becoming appar-
ent at the 5th day. Unfortunately it was
not possible to continue CEA estimations
for longer, because the effect of further
marrow suppression on already immune-
suppressed animals delayed recovery from
the anaemia of serial venesection too long
to permit further study.
D)ISCUSSION
Previous in vitro experiments have
provided some support for the hypothesis
that CEA may be released as a result of
tumour lysis. Several workers have shown
that CEA is released from cells during the
stationary phase of the cell cycle (Drew-
inko & Yang, 1976, 1980: Goldenberg
et al., unpub.). Ellison et al. (1977) and
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FIG. 4. CEA blood levels after X-rays (p246
lung) (in parentheses, percentage change
in tumour volume).
Goldenberg et al. (unpub.) originally
demonstrated that when toxic conditions
were introduced to cell lines, up to a 25-
fold increase in CEA would appear in
culture media over a short interval,
whereas when growth rate was accelerated,
by increasing the temperature or adding
cyclic AMP, a reduction in CEA occurred,
and this has been further confirmed more
recently by Drewinko & Yang (1980). By
implication, CEA release would appear to
be maximal when the "health" of the cell
was compromised.
The human in vivo responses supporting
this hypothesis which were described in
the introduction should, however, be
regarded with some circumspection,
because there may be many otherprocesses
operating.
The demonstration in this study of
numerous instances when effective tumour
lysis resulted in peak elevations of circula-
ting CEA, does suggest that tumour necro-
sis and/or factors associated with this
process may play a part in the release of
(43%)
(15%)
(16l)
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FiG. 5. CEA levels after HMM (p246 lung)
(in parentheses, percentage ch-ange in
tumour volume).
CEA. HBowever, in extrapolating fronm
data of these xenograft studies, it is
essential to appreciate that the same may
not apply in patients. The conditions were
grossly artificial and the methods for
inducing tumour necrosis were extreme.
As yet no such treatment as effective as
diphtheria toxin on the xenograft model
is available to clinical practice.
It was surprising, however, that in the
HK9 colon tumours, which were by far
the best responders to diphtheria toxin,
the changes in blood CEA were the least
remarkable among the whole colon (HK)
tumour group.
The concentration of CEA in the cir-
culation is likely to be maintained in a
state of dynamic equilibrium by a set of
complex factors affecting the source of
CEA in the tissues, the processes by which
it is released from tumour tissue into the
blood, and its subsequent metabolism.
Whilst tumour lysis may be a factor
responsible for elevated blood CEA
levels, it would seem unlikely to make a
218
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major contribution to the many other
factors, unless the process were extensive
and rapid. The possibility should continue
to be entertained, however, that tumour
lysis may in part be responsible for the
discordant changes which take place in
patients during chemo- and radiotherapy.
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